Hypera SA
BOVESPA:HYPE3
Hypera SA
EPS (Diluted)
Hypera SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hypera SA
BOVESPA:HYPE3
|
EPS (Diluted)
R$2
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
13%
|
|
|
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
|
EPS (Diluted)
R$15
|
CAGR 3-Years
93%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
Hypera SA
Glance View
Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.
See Also
What is Hypera SA's EPS (Diluted)?
EPS (Diluted)
2.1
BRL
Based on the financial report for Dec 31, 2024, Hypera SA's EPS (Diluted) amounts to 2.1 BRL.
What is Hypera SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
13%
Over the last year, the EPS (Diluted) growth was -18%.
You don't have any saved screeners yet